Worth knowing before you pay
NFT-dependent elevation of glutathione levels even protected the cells from subsequent treatment with toxic NFT concentrations
2024 DOI: 10.1038/s41421-024-00702-y PMID: 39019866 Read on PubMed European Journal of Clinical Pharmacology A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity Kaur M, Misra S 2024 DOI: 10.1007/s00228-024-03646-0 PMID: 38367045 Read on PubMed Cardiology in Review The First Triple Agonist for Antiobesity: Retatrutide Tetelbaum L, Mullally JA, Frishman WH 2024 DOI: 10.1097/CRD.0000000000000793 PMID: 39724554 Read on PubMed NPJ Metabolic Health and Disease Incretin triple agonist retatrutide alleviates obesity-associated cancer progression Marathe SJ, Grey EW, Bohm MS, et al
Placebo Common Dosages (Under Investigation) While dosing is still being refined, trial protocols have tested: 1 mg 12 mg weekly , typically titrated over time to reduce GI side effects
Understanding the Side Effects Like all medications, GLP-1 drugs can cause side effects
